Cystic-fibrosis drug gets first clinical trial

N30 Pharmaceuticals Inc. in Boulder announced Wednesday that it has administered, in a clinical trial, the first dose of a drug designed to treat cystic fibrosis.

The drug, labeled N6022, was administered this week to a patient at National Jewish Health in Denver. Continue reading Cystic-fibrosis drug gets first clinical trial

Stem cell line could also advance research into liver cancers, cystic fibrosis

Published on March 1, 2013 at 12:00 AM
Chronic or acute, liver failure can be deadly. Toxins take over, the skin turns yellow and higher brain function slows.

“There is no effective therapy at the moment to deal with the toxins that build up in your body,” Continue reading Stem cell line could also advance research into liver cancers, cystic fibrosis

Vertex Readies Late-Stage Cystic Fibrosis Drug Studies

Vertex Pharmaceuticals (VRTX) announced Tuesday night the design of two phase III studies for its combination therapy to treat the most common form of cystic fibrosis. The studies will each run for six months, so results could be ready as early as the end of 2013 or during first half of 2014.

If the studies are positive, Vertex intends to file for U.S. approval in 2014. Continue reading Vertex Readies Late-Stage Cystic Fibrosis Drug Studies

Pharma And Biotech

Promising pre-clinical data in Cystic Fibrosis for ProtAffin AGs PA401 to be presented at ATS, Philadelphia, 17-22 May 2013

ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for inflammation, respiratory disease and oncology, has announced that a collaboration with a leading European centre for the study of cystic fibrosis has generated Continue reading Pharma And Biotech

‘Bloodless’ Lung Transplants Offer Hint at Surgery’s Future

Last April, after being told that only a transplant could save her from a fatal lung condition, Rebecca S. Tomczak began calling some of the top-ranked hospitals in the country.
She started with Emory University Hospital in Atlanta, just hours from her home near Augusta, Ga. Then she tried Duke and the University of Arkansas and Johns Hopkins. Each advised Ms. Continue reading ‘Bloodless’ Lung Transplants Offer Hint at Surgery’s Future

A solution to sinusitis from the sea

A team of scientists and surgeons from Newcastle are developing a new nasal spray from a marine microbe to help clear chronic sinusitis.

They are using an enzyme isolated from a marine bacterium Bacillus licheniformis found on the surface of seaweed which the scientists at Newcastle University were originally researching for the purpose of cleaning the hulls of ships.

 Continue reading A solution to sinusitis from the sea

Promising pre-clinical data in Cystic Fibrosis for ProtAffin AG’s PA401 to be presented at ATS, Philadelphia, 17-22 May 2013

Graz, Austria and London, UK- 20th February 2013: ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for inflammation, respiratory disease and oncology, today announced that a collaboration with a leading European centre for the Continue reading Promising pre-clinical data in Cystic Fibrosis for ProtAffin AG’s PA401 to be presented at ATS, Philadelphia, 17-22 May 2013

Discovery Of ‘Switch’ That Turns On Aggressive Infection In Superbug Offers Potential New Target For Treatment

University of Cambridge researchers have discovered how an antibiotic-resistant superbug exploits oxygen-limited conditions in the lungs of patients with severe respiratory disease to thrive.

It is hoped the discovery could lead to new ways to target the Pseudomonas aeruginosabacterium, Continue reading Discovery Of ‘Switch’ That Turns On Aggressive Infection In Superbug Offers Potential New Target For Treatment

KaloBios Initiates Phase 2 Study with KB001-A Humaneered® Monoclonal Antibody in Cystic Fibrosis Patients

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB001-A, the company’s anti-PcrV Humaneered®, PEGylated monoclonal antibody fragment. The study will investigate the safety and efficacy of intravenously administered KB001-A as a treatment for chronic Pseudomonas aeruginosa (Pa) infection in cystic fibrosis patients. Continue reading KaloBios Initiates Phase 2 Study with KB001-A Humaneered® Monoclonal Antibody in Cystic Fibrosis Patients

Special Webinar on CF Care

Date: Wednesday, December 12th
Time: 2:00 pm – 3:00pm Eastern time
Title: Providing Best Care for Individuals with Cystic Fibrosis: A Partnership with Patients and Families
Speaker: Dr. Michael Boyle, Director of the Adult CF Center at Johns Hopkins Medicine.

Don’t miss this chance to learn about ways to obtain the best care from your healthcare team.  Dr. Boyle is one of the leading CF adult physicians in the United States and is sure to share some helpful information. Continue reading Special Webinar on CF Care